Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kyowa Kirin Co., Ltd. (4151.T)
Tokyo, JP
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.22% | -2.85% | -9.14% | -9.26% | -5.03% | -7.26% | +8.95% | -11.62% | -28.15% | +17.28% | +227.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 3 | 0 |
| Sell | 3 | 0 |
| Strong Sell | 3 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+0.3% Q1'26: +13.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+13.3% Q1'26: +95.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+11.6% Q1'26: +37.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+20.6% ★ Q1'26: +14.5% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+11.2% ★ Q1'26: +9.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-1.2% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.20× ★ Q1'26: 0.22× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 11 EPS Ana. |
Dec 2027 11 Rev. Ana. 11 EPS Ana. |
Dec 2028 10 Rev. Ana. 10 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
364.32B
est: 362.72B (+0.4%)
|
347.96B
est: 346.89B (+0.3%)
|
353.38B
est: 348.20B (+1.5%)
|
271.51B
est: 341.16B (-20.4%)
|
305.82B
est: 305.44B (+0.1%)
|
318.35B
est: 319.02B (-0.2%)
|
352.25B
est: 350.56B (+0.5%)
|
398.37B
est: 396.53B (+0.5%)
|
442.23B
est: 476.00B (-7.1%)
|
495.56B
est: 490.91B (+0.9%)
|
496.83B
est: 483.78B (+2.7%)
|
522.18B
510.15B – 530.52B
+7.9% YoY
|
538.76B
524.05B – 551.91B
+3.2% YoY
|
546.25B
544.04B – 548.46B
+1.4% YoY
|
590.11B
575.24B – 602.06B
+8.0% YoY
|
581.00B
566.37B – 592.77B
-1.5% YoY
|
| EBITDA |
80.32B
est: 82.09B (-2.1%)
|
75.25B
est: 78.50B (-4.1%)
|
84.24B
est: 78.80B (+6.9%)
|
66.65B
est: 77.21B (-13.7%)
|
72.15B
est: 69.12B (+4.4%)
|
75.89B
est: 72.20B (+5.1%)
|
80.61B
est: 79.33B (+1.6%)
|
100.85B
est: 89.74B (+12.4%)
|
116.94B
est: 132.59B (-11.8%)
|
116.65B
est: 136.74B (-14.7%)
|
128.42B
est: 134.75B (-4.7%)
|
145.45B
142.10B – 147.77B
+7.9% YoY
|
150.07B
145.97B – 153.73B
+3.2% YoY
|
152.15B
151.54B – 152.77B
+1.4% YoY
|
164.37B
160.23B – 167.70B
+8.0% YoY
|
161.83B
157.76B – 165.11B
-1.5% YoY
|
| EBIT |
43.77B
est: 62.95B (-30.5%)
|
51.47B
est: 60.21B (-14.5%)
|
62.21B
est: 60.43B (+2.9%)
|
50.40B
est: 59.21B (-14.9%)
|
53.35B
est: 53.01B (+0.6%)
|
55.42B
est: 55.37B (+0.1%)
|
61.11B
est: 60.84B (+0.4%)
|
82.38B
est: 68.82B (+19.7%)
|
95.84B
est: 107.93B (-11.2%)
|
91.87B
est: 111.31B (-17.5%)
|
102.28B
est: 109.69B (-6.8%)
|
118.40B
115.67B – 120.29B
+7.9% YoY
|
122.16B
118.82B – 125.14B
+3.2% YoY
|
123.85B
123.35B – 124.35B
+1.4% YoY
|
133.80B
130.43B – 136.51B
+8.0% YoY
|
131.73B
128.41B – 134.40B
-1.5% YoY
|
| Net Income |
29.77B
est: 27.06B (+10.0%)
|
30.45B
est: 19.22B (+58.4%)
|
42.90B
est: 21.96B (+95.3%)
|
54.41B
est: 51.49B (+5.7%)
|
23.25B
est: 64.56B (-64.0%)
|
47.03B
est: 47.24B (-0.4%)
|
52.35B
est: 49.97B (+4.8%)
|
53.57B
est: 58.32B (-8.1%)
|
81.19B
est: 97.32B (-16.6%)
|
59.87B
est: 68.12B (-12.1%)
|
67.04B
est: 54.77B (+22.4%)
|
77.01B
66.88B – 96.19B
+40.6% YoY
|
84.14B
65.16B – 96.84B
+9.3% YoY
|
82.89B
70.25B – 92.41B
-1.5% YoY
|
86.84B
84.00B – 89.13B
+4.8% YoY
|
74.24B
71.81B – 76.20B
-14.5% YoY
|
| SGA |
105.70B
est: 135.92B (-22.2%)
|
100.24B
est: 129.98B (-22.9%)
|
104.61B
est: 130.47B (-19.8%)
|
110.28B
est: 127.84B (-13.7%)
|
106.25B
est: 114.45B (-7.2%)
|
116.53B
est: 119.54B (-2.5%)
|
135.11B
est: 131.36B (+2.9%)
|
166.19B
est: 148.58B (+11.8%)
|
163.08B
est: 170.56B (-4.4%)
|
155.81B
est: 175.90B (-11.4%)
|
152.90B
est: 173.35B (-11.8%)
|
187.11B
182.80B – 190.10B
+7.9% YoY
|
193.05B
187.78B – 197.76B
+3.2% YoY
|
195.73B
194.94B – 196.53B
+1.4% YoY
|
211.45B
206.12B – 215.73B
+8.0% YoY
|
208.19B
202.94B – 212.40B
-1.5% YoY
|
| EPS |
54.40
est: 51.10 (+6.4%)
|
55.64
est: 36.30 (+53.3%)
|
78.38
est: 41.47 (+89.0%)
|
99.40
est: 97.23 (+2.2%)
|
43.16
est: 121.91 (-64.6%)
|
87.56
est: 89.20 (-1.8%)
|
97.43
est: 94.36 (+3.2%)
|
99.68
est: 110.13 (-9.5%)
|
151.03
est: 181.65 (-16.9%)
|
113.06
est: 130.55 (-13.4%)
|
128.07
est: 104.97 (+22.0%)
|
154.99
127.76 – 183.76
+47.7% YoY
|
161.20
124.49 – 184.99
+4.0% YoY
|
157.18
134.20 – 176.53
-2.5% YoY
|
165.90
160.47 – 170.27
+5.6% YoY
|
141.83
137.19 – 145.57
-14.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-14 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Masashi Miyamoto | Chairman & Chief Executive Officer | 157M | male |
| Abdul Hafeez Mullick | President, Chief Executive Officer & Representative Director | 157M | — |
| Hiroki Nakamura | Global Corporate Communications Head | — | — |
| Hiroshi Sonekawa | Managing Executive Officer, Vice President and Head of Sales & Marketing Division | — | — |
| Katsuyoshi Tsukii | Executive Officer, VP & Head of Development Division | — | — |
| Kazuki Nemoto | Head of Global Legal | — | — |
| Koichi Nagano | Executive Officer and Head of Tokyo Branch - Sales & Marketing Division | — | — |
| Koji Igarashi | Chief Financial Officer | — | male |
| Masahiro Hara | Global Procurement Head | — | male |
| Motohiko Kawaguchi | Chief Financial Officer & Managing Executive Officer | — | male |
| Naohiko Kubo | Global Finance Head & Accounting Manager | — | — |
| Nathan Hawes | Global Operational & Digital Transformation Head | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4151.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
